• Translarna Improved Activity Measures in Phase 3 Trial, But Results Lack Significance
  • Phrixus, DMD Groups Plan First Clinical Trial of Potential Duchenne Therapy Already Used in Europe
  • ‘Coach to Cure MD’ and Other Fundraising Events Mark Duchenne Muscular Dystrophy Month
  • Santhera to Appeal European Agency’s Decision Against Raxone as a Duchenne MD Therapy
  • Tips and Tricks to Stay Positive when You Have a Disability
  • Jerry Mendell, in PPMD Webinar, Details Plans for Possible Trial of Duchenne Gene Therapy
  • Shortened Telomeres Linked to Muscle Degeneration in Duchenne, Study Finds
  • Utah Researcher Receives Grant to Study Stages of Congenital Myotonic Dystrophy
  • First DMD Patients to Receive Raxone Under U.K.’s Early Access Program
  • Sarepta’s Exon 53 Skipping Therapy, Golodirsen, Improves Dystrophin Expression in Phase 1/2 Trial
  • On World Duchenne Awareness Day, Winners of 2017 STRIVE Awards Announced
  • Parent Project Muscular Dystrophy Holding Duchenne Action Month During September